Cellular Expression or Binding of desLys58‐β2 Microglobulin is not Dependent on the Presence of the Tri‐molecular MHC Class I Complex

The monoclonal antibody 332‐01 is a newly developed antibody which specifically recognizes human desLys58‐β2 microglobulin (dβ2m). In the present study, we characterized the binding of 332‐01 to peripheral blood mononuclear cells (PBMC), a number of human leukaemic and monocytic cell lines, and β2m gene‐deleted murine lymphocytes. dβ2m was found to be expressed on non‐activated and activated monocytes. When cells were pre‐exposed to dβ2m, 332‐01 also bound to non‐activated T lymphocytes. dβ2m was expressed on the monocytic cell lines U937 and TIB‐202, and binding was significantly increased when cells were pre‐incubated with dβ2m and when TIB‐202 cells were exposed to lipopolysaccharide. dβ2m was also expressed on T leukaemic Jurkat cells as well as on low HLA‐expressing erythroleukaemic K562 cells. β2m gene‐deleted murine splenocytes only bound 332‐01 after pre‐exposure to dβ2m. Binding of 332‐01 antibody could not be displaced by addition of high concentrations of native β2m. In conclusion, our data indicate that dβ2m – in contrast to native β2m – binds to a hitherto unknown cell surface receptor independent of classical MHC class I molecules. As β2m has previously been shown to display biological activities such as the induction of both growth promotion and apoptosis, C1 complement activity, shown to mediate cleavage of β2m, could be involved in these processes.

[1]  S. Skov Intracellular signal transduction mediated by ligation of MHC class I molecules. , 2008, Tissue antigens.

[2]  D. B. Corlin,et al.  Variants of β2‐microglobulin cleaved at lysine‐58 retain the main conformational features of the native protein but are more conformationally heterogeneous and unstable at physiological temperature , 2006, The FEBS journal.

[3]  D. B. Corlin,et al.  Quantification of Cleaved β2-Microglobulin in Serum from Patients Undergoing Chronic Hemodialysis , 2005 .

[4]  P. Roepstorff,et al.  Unfolding, aggregation, and seeded amyloid formation of lysine-58-cleaved beta 2-microglobulin. , 2005, Biochemistry.

[5]  A. Jenei,et al.  Class I HLA oligomerization at the surface of B cells is controlled by exogenous beta(2)-microglobulin: implications in activation of cytotoxic T lymphocytes. , 2003, International immunology.

[6]  A. Safa,et al.  Mechanism of beta 2-microglobulin-induced apoptosis in the K562 leukemia cell line, defective in major histocompatibility class 1. , 2002, Anticancer Research.

[7]  B. Barlogie,et al.  β2‐microglobulin as a negative growth regulator of myeloma cells , 2002, British journal of haematology.

[8]  P. Roepstorff,et al.  Cleaved β2-Microglobulin Partially Attains a Conformation That Has Amyloidogenic Features* , 2002, The Journal of Biological Chemistry.

[9]  A. Safa,et al.  β2-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein , 2001, Oncogene.

[10]  H. Hayasawa,et al.  Antitumor Effect of β2-Microglobulin in Leukemic Cell-bearing Mice via Apoptosis-inducing Activity Activation of Caspase-3 and Nuclear Factor-κB , 2001 .

[11]  H. Mano,et al.  β2-Microglobulin Identified as an Apoptosis-Inducing Factor and Its Characterization , 1999 .

[12]  M. Claesson,et al.  Signal transduction by the major histocompatibility complex class I molecule: , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  M. Claesson,et al.  C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. , 1998, International immunology.

[14]  M. Claesson,et al.  Ligation of Major Histocompatability Complex (MHC) Class I Molecules on Human T Cells Induces Cell Death through PI-3 Kinase–induced c-Jun NH2-terminal Kinase Activity: A Novel Apoptotic Pathway Distinct from Fas-induced Apoptosis , 1997, The Journal of cell biology.

[15]  B. Johansen,et al.  A simple method for the preparation and purification of C1 complement cleaved beta 2-microglobulin from human serum. , 1997, Journal of immunological methods.

[16]  M. Claesson,et al.  MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis. , 1997, Journal of immunology.

[17]  M. Claesson,et al.  Ligation of MHC class I molecules on peripheral blood T lymphocytes induces new phenotypes and functions. , 1996, Journal of immunology.

[18]  O. Majdic,et al.  Expression of β2‐microglobulin‐free HLA class I α‐chains on activated T cells requires internalization of HLA class I heterodimers , 1996, Immunology.

[19]  M. Gerdes,et al.  β-2 Microglobulin Is Mitogenic to PC-3 Prostatic Carcinoma Cells and Antagonistic to Transforming Growth Factor β1 Action , 1995 .

[20]  S. Demaria,et al.  The origin and fate of β2m-free MHC class I molecules induced on activated T cells , 1992 .

[21]  L. Chess,et al.  Specific triggering of gamma, delta T cells by K562 activates the gamma, delta T cell receptor and may regulate natural killer-like function. , 1991, Journal of immunology.

[22]  A. Vitiello,et al.  The role of beta 2-microglobulin in peptide binding by class I molecules. , 1990, Science.

[23]  O. Bjerrum,et al.  Neutrophil Beta‐2 Microglobulin: an Inflammatory Mediator , 1990, Scandinavian journal of immunology.

[24]  F. Lemonnier,et al.  β2-Microglobulin restriction of antigen presentation , 1990, Nature.

[25]  P. Roepstorff,et al.  Limited proteolysis of β2-microglobulin at Lys-58 by complement component C1s , 1990 .

[26]  E. Canalis,et al.  Beta 2-microglobulin enhances insulin-like growth factor I receptor levels and synthesis in bone cell cultures. , 1989, The Journal of biological chemistry.

[27]  E. Cooper,et al.  A method to detect the in vitro modification of serum beta-2-microglobulin in health and disease. , 1988, Clinica chimica acta; international journal of clinical chemistry.

[28]  M. Nissen,et al.  Proteolytically modified human beta 2-microglobulin augments the specific cytotoxic activity in murine mixed lymphocyte culture. , 1987, Journal of immunology.

[29]  O. Bjerrum,et al.  Beta 2-microglobulin in neutrophils: an intragranular protein. , 1987, Journal of immunology.

[30]  L. Thim,et al.  Purification and biochemical characterization of the complete structure of a proteolytically modified beta-2-microglobulin with biological activity. , 1987, European journal of biochemistry.

[31]  M. Schwartz,et al.  Beta 2-microglobulin as a prognostic marker for development of AIDS. , 1985, Clinical chemistry.

[32]  M. Ro̸rth,et al.  Modification of beta 2-microglobulin in serum from patients with small cell carcinoma of the lung--correlation with the clinical course. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[33]  K. Parker,et al.  Sequence of human β2-microglobulin: A correction , 1982 .

[34]  E. Kawashima,et al.  Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Plesner,et al.  Distribution of ‘Free’ and HLA‐associated Human β2‐Microglobulin in Some Plasma Membranes and Biological Fluids , 1980, Scandinavian journal of immunology.

[36]  A. Wiik,et al.  Demonstration of Electrophoretic Heterogeneity of Serum β2‐Microglobulin in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Evidence against Autoantibodies to β2‐Microglobulin , 1979, Scandinavian journal of immunology.

[37]  P. A. Peterson,et al.  The complete amino acid sequence of beta 2-microglobulin. , 1973, Biochemistry.

[38]  I. Berggård,et al.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids. , 1968, The Journal of biological chemistry.

[39]  D. B. Corlin,et al.  Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. , 2005, Clinical chemistry.

[40]  D. Moody,et al.  Intracellular pathways of CD1 antigen presentation , 2003, Nature Reviews Immunology.

[41]  H. Hayasawa,et al.  Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB. , 2001, Cancer research.

[42]  H. Mano,et al.  Beta(2)-microglobulin identified as an apoptosis-inducing factor and its characterization. , 1999, Blood.

[43]  K. Rock,et al.  Antigen processing and presentation by the class I major histocompatibility complex. , 1996, Annual review of immunology.

[44]  M. Gerdes,et al.  Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. , 1995, Cancer research.

[45]  S. Demaria,et al.  The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells. , 1992, Cellular Immunology.

[46]  P. Roepstorff,et al.  Limited proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s. , 1990, European journal of biochemistry.

[47]  F. Lemonnier,et al.  Beta 2-microglobulin restriction of antigen presentation. , 1990, Nature.

[48]  J Sodek,et al.  Bone cell cultures. , 1987, Methods in enzymology.

[49]  B. No̸rgaard-Pedersen,et al.  Radiocrossed immunoelectrophoretical heterogeneity of beta 2-microglobulin in blood from patients with germ cell tumors and with colorectal cancer. , 1983, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[50]  K. Parker,et al.  Sequence of human beta 2-microglobulin: a correction. , 1982, Molecular Immunology.